Shinpoong Pharmaceutical신풍제약
019170 · KOSPI · ₩019170 · 신풍제약
₩8,410▼ ₩50 (0.59%)End-of-day · Oct 29, 2026 · End-of-day prices.
Filings
- Major management matter relevant to investors투자판단관련주요경영사항 (급성 허혈성 뇌졸중 치료제 SP8203 임상 3상 시험변경계획 승인)Oct 22, 2026Open on DART
Predicted impact: Medium
Approval of a change to the Phase 3 trial plan for stroke drug SP8203; no size given.
- Major management matter relevant to investors투자판단관련주요경영사항 (급성 허혈성 뇌졸중 치료제 SP8203 임상 3상 시험변경계획 승인 신청)Sep 15, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
- Disclosure of Corporate Governance Report기업지배구조보고서공시May 29, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 30, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 30, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 20, 2026Open on DART
- Audit report submitted감사보고서제출Mar 19, 2026Open on DART
- Notice of Reason for Concentrated Shareholders' Meeting Date주주총회집중일개최사유신고Mar 10, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Mar 10, 2026Open on DART
- Amended: Change in revenue or profit of 30% or more[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변경Mar 10, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 10, 2026Open on DART
- Amended: Acquisition of shares in another company[기재정정]타법인주식및출자증권취득결정Feb 27, 2026Open on DART
- Report on Results of Disposal of Treasury Shares자기주식처분결과보고서Feb 27, 2026Open on DART
- Share cancellation decision주식소각결정Feb 26, 2026Open on DART
- Acquisition of shares in another company타법인주식및출자증권취득결정Feb 26, 2026Open on DART
- Treasury share sale decision주요사항보고서(자기주식처분결정)Feb 26, 2026Open on DART
- Change in revenue or profit of 30% or more매출액또는손익구조30%(대규모법인은15%)이상변경Feb 23, 2026Open on DART
- Sales or supply contract terminated단일판매ㆍ공급계약해지Jan 14, 2026Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 11, 2025Open on DART
- Results of Rights Offering or Issuance of Equity-Linked Bonds, etc. (Voluntary Disclosure)유상증자또는주식관련사채등의발행결과(자율공시)Dec 3, 2025Open on DART
- Report on Results of Disposal of Treasury Shares자기주식처분결과보고서Dec 3, 2025Open on DART
- Amended: Treasury share sale decision[기재정정]주요사항보고서(자기주식처분결정)Dec 2, 2025Open on DART
- Amended: Exchangeable bond issue decision[기재정정]주요사항보고서(교환사채권발행결정)Dec 2, 2025Open on DART
- Amended: Treasury share sale decision[기재정정]주요사항보고서(자기주식처분결정)Dec 1, 2025Open on DART
- Amended: Exchangeable bond issue decision[기재정정]주요사항보고서(교환사채권발행결정)Dec 1, 2025Open on DART
- Treasury share sale decision주요사항보고서(자기주식처분결정)Nov 25, 2025Open on DART
- Exchangeable bond issue decision주요사항보고서(교환사채권발행결정)Nov 25, 2025Open on DART
- New Facility Investment, etc.신규시설투자등Nov 20, 2025Open on DART
- Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 14, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (유행성 RNA 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물_미국특허취득)Oct 24, 2025Open on DART
- Amended: Annual report (Dec 2024)[기재정정]사업보고서 (2024.12)Aug 14, 2025Open on DART
- Half-year report (Jun 2025)반기보고서 (2025.06)Aug 14, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (유행성 RNA 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물_국내특허취득)Jun 27, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (유행성 RNA 바이러스 감염질환의 예방 또는 치료용 약제학적 조성물_특허취득)Jun 16, 2025Open on DART
- Designation as Company for Unfaithful Disclosure불성실공시법인지정May 30, 2025Open on DART
- Amended: Quarterly report (Mar 2025)[기재정정]분기보고서 (2025.03)May 15, 2025Open on DART
- Quarterly report (Mar 2025)분기보고서 (2025.03)May 15, 2025Open on DART
- Notice of Planned Designation as Unfaithful Disclosure Company불성실공시법인지정예고May 12, 2025Open on DART
- Confirmation of Embezzlement/Breach of Trust횡령ㆍ배임사실확인May 8, 2025Open on DART
- Major management matter relevant to investors투자판단관련주요경영사항 (골관절염 주사요법제 SP5M002주의 임상 3상 시험 Topline 결과 발표)Apr 3, 2025Open on DART
- Annual general meeting results정기주주총회결과Mar 28, 2025Open on DART
- Added attachment: Annual report (Dec 2024)[첨부추가]사업보고서 (2024.12)Mar 20, 2025Open on DART
- Audit report submitted감사보고서제출Mar 19, 2025Open on DART
- Amended: Change in revenue or profit of 30% or more[기재정정]매출액또는손익구조30%(대규모법인은15%)이상변경Mar 7, 2025Open on DART
- Notice of Reason for Concentrated Shareholders' Meeting Date주주총회집중일개최사유신고Mar 7, 2025Open on DART
- Shareholders' meeting called주주총회소집결의Mar 7, 2025Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 7, 2025Open on DART
- Change in revenue or profit of 30% or more매출액또는손익구조30%(대규모법인은15%)이상변경Feb 21, 2025Open on DART
Titles in Korean until English translations are added.
Also known as: Shinpoong Pharmaceutical / 신풍제약 / 019170 / KRX:019170
Source: KRX statistical information